Cerapedics, a privately-held orthobiologics company, today announced the company received approval from the U.S. Food and Drug Administration (FDA) to initiate an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of P-15L Peptide Enhanced Bone Graft compared to autograft in transforaminal lumbar interbody fusion (TLIF) surgery for degenerative disk disease.
Results published in Neurosurgery show peptide enhanced bone graft statistically superior to autograft in ACDF procedures at two years.
ALEXANDRIA, Va. and WESTMINSTER, Colo.– April 19, 2017 – Oxford Finance LLC (“Oxford”), an industryleading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $20 million senior secured term loan with Cerapedics Inc. (“Cerapedics”) a privately-held orthobiologics company engaged in the development and commercialization
Contract awarded for Breakthrough Technology: Bone Tissue Synthetic Implantable Products.
Award recognizes i-FACTOR™ Peptide Enhanced Bone Graft based on the company’s synthetic small peptide (P-15) technology.
Results published in peer‐reviewed journal Spine show peptide enhanced bone graft is safe and effective when compared to local autograft in ACDF procedures.
Orthobiologics company positioned to begin commercial distribution in the U.S. following successful Premarket Approval application.